Verana Health’s merger with COTA expands real-world data and analytics capabilities across oncology and specialty care, strengthening research-ready evidence generation for biopharma, regulatory decision-making, and clinical development.
Verana Health has announced a merger with COTA, Inc., bringing together two real-world data (RWD) and analytics providers to broaden therapeutic coverage and strengthen research-ready evidence generation for life sciences organizations.1
The merger expands Verana Health’s data and software capabilities across oncology, ophthalmology, urology, and neurology, while deepening access to clinically rich real-world insights designed to support clinical research, regulatory decision-making, and patient care optimization.
The combination strengthens Verana Health’s existing real-world evidence (RWE) platform by integrating COTA’s oncology-focused datasets and analytics. Together, the companies aim to deliver deeper, more clinically validated real-world data capable of meeting the rigor required for clinical development and regulatory submissions.
Verana Health’s platform has been used to support clinical trials, drug submissions, health economics and outcomes research, and market-access strategies, as well as MIPS advisory services for clinicians. COTA’s oncology expertise complements these capabilities by enabling advanced curation and analysis of data sourced from dozens of academic medical centers.
In a company statement, Sujay Jadhav, CEO of Verana Health, said the merger represents a significant step forward for the company’s multi-therapeutic strategy.
"We're very excited to welcome COTA as we significantly broaden and amplify our capabilities for the life sciences community," Jadhav said. "This is a unique opportunity to better serve organizations with advanced curation technology and real-world insights across multiple specialty therapeutic areas. This combination raises the bar for clinical expertise, data quality, validation, and transparency, so our partners can generate evidence with the utmost confidence."
CK Wang, MD, CEO of COTA, emphasized the shared focus on data quality and patient impact.
"We're pleased to join with Verana Health and bring together two exceptional and unique companies delivering real-world data solutions for the life sciences industry," Wang said. "Our shared commitment to advancing high-quality data and service offerings will help support the discovery of new treatment protocols and ultimately transform patient care."
The merged organization also brings together deep regulatory expertise, positioning the company as a strategic partner for biopharma organizations working closely with the FDA. By combining oncology-focused RWD with specialty registry data and advanced analytics, the joint entity aims to accelerate evidence generation while maintaining regulatory-grade standards.
Applied Clinical Trials caught up with both Jadhav and Wang in 2025 to discuss the growing roles of RWD and RWE in clinical research as well as how artificial intelligence can fit alongside them.
In a video interview, Jadhav
Wang
“When used appropriately, RWD and RWE can really help us address the challenge of how to best treat certain groups of patients in all clinical scenarios, and not just the specific clinical setting that that we get from the clinical trials,” he said. “I think that additionally, real-world data has the potential to help us expedite the way clinical trials are being conducted.”
1. Verana Health Merges with COTA to Dramatically Expand Scale, Velocity, and Depth of Real-World Data Offerings Across Oncology and Other Specialties. News release. Verana Health. January 8, 2026. Accessed January 8, 2026.
